JP2014530360A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530360A5
JP2014530360A5 JP2014533883A JP2014533883A JP2014530360A5 JP 2014530360 A5 JP2014530360 A5 JP 2014530360A5 JP 2014533883 A JP2014533883 A JP 2014533883A JP 2014533883 A JP2014533883 A JP 2014533883A JP 2014530360 A5 JP2014530360 A5 JP 2014530360A5
Authority
JP
Japan
Prior art keywords
antibody
deposit
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014533883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530360A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014530360A publication Critical patent/JP2014530360A/ja
Publication of JP2014530360A5 publication Critical patent/JP2014530360A5/ja
Pending legal-status Critical Current

Links

JP2014533883A 2011-10-07 2012-10-04 診断マーカーとしてのｏｘＭＩＦ Pending JP2014530360A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161545042P 2011-10-07 2011-10-07
US61/545,042 2011-10-07
US201261624943P 2012-04-16 2012-04-16
US61/624,943 2012-04-16
US201261668841P 2012-07-06 2012-07-06
US61/668,841 2012-07-06

Publications (2)

Publication Number Publication Date
JP2014530360A JP2014530360A (ja) 2014-11-17
JP2014530360A5 true JP2014530360A5 (cg-RX-API-DMAC10.html) 2015-11-12

Family

ID=46980957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014533883A Pending JP2014530360A (ja) 2011-10-07 2012-10-04 診断マーカーとしてのｏｘＭＩＦ

Country Status (8)

Country Link
US (1) US9958456B2 (cg-RX-API-DMAC10.html)
EP (1) EP2748613B1 (cg-RX-API-DMAC10.html)
JP (1) JP2014530360A (cg-RX-API-DMAC10.html)
AR (1) AR088244A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012320597C1 (cg-RX-API-DMAC10.html)
HK (1) HK1198591A1 (cg-RX-API-DMAC10.html)
TW (1) TW201321408A (cg-RX-API-DMAC10.html)
WO (1) WO2013050453A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
CA2878494A1 (en) * 2012-07-10 2014-01-16 Baxter Healthcare S.A. Anti-mif immunohistochemistry
US9536304B2 (en) * 2013-08-30 2017-01-03 Dairy Quality Inc. Determining pathogens based on an image of somatic cells in a fluid sample
KR20160073382A (ko) * 2013-10-04 2016-06-24 셀 아이디어스 피티와이 엘티디 세포 치료를 위한 바이오마커들
EP3090262B1 (en) * 2014-01-03 2018-08-01 Baxalta GmbH Anti-mif immunohistochemistry
US10626166B2 (en) 2014-08-22 2020-04-21 Baxalta Incorporated Detection of CHO-MIF contaminations
US20220002398A1 (en) * 2018-06-07 2022-01-06 Oncoone Research & Development Gmbh ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
EP4069735A1 (en) * 2019-12-06 2022-10-12 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 bispecific antibody constructs
KR20230142738A (ko) * 2021-02-03 2023-10-11 온코원 리서치 앤드 디벨롭먼트 게엠베하 항-oxMIF 방사성면역접합체

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299814A (en) 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
JPH0672158B2 (ja) 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト 精製されたヒトマクロファージ遊走阻止因子
US4946674A (en) 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
US4708937A (en) 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3789413T2 (de) 1986-10-03 1994-07-28 Ciba Geigy Ag Lymphokin-ähnliche Peptide.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990011301A1 (en) 1989-03-17 1990-10-04 Genetics Institute, Inc. Human macrophage migration inhibitory factor
US5785054A (en) 1989-06-06 1998-07-28 Kelly; Patrick D. Genital lubricant with zinc salt, labelled as anti-viral agent
GB8915414D0 (en) 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
EP0457875A4 (en) 1989-11-13 1993-03-03 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5227459A (en) 1990-05-18 1993-07-13 Yale University Synthetic melanin
US5786168A (en) 1990-06-04 1998-07-28 Kirin Beer Kabushiki Kaisha Method for recombinant production of antigen non-specific glycosylation inhibiting factor (GIF)
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
WO1994026307A1 (en) 1993-05-17 1994-11-24 The Picower Institute For Medical Research Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
US6645493B1 (en) 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US5559028A (en) 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
AU7394294A (en) 1994-05-16 1995-12-05 Human Genome Sciences, Inc. Macrophage migration inhibitory factor-3
US5747023A (en) 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
SI9400363A (en) 1994-09-19 1996-08-31 Mozetic Francky Bojana Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein
WO1996015242A2 (en) 1994-11-16 1996-05-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
JPH0977799A (ja) 1995-09-13 1997-03-25 Sapporo Immuno Diagnostic Lab:Kk ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ
WO1997025344A1 (en) 1996-01-03 1997-07-17 The Australian National University Clip analogues and autoimmune disease
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US5726020A (en) 1996-06-11 1998-03-10 University Of Massachusetts Inhibition of II synthesis
US6297253B1 (en) 1996-10-15 2001-10-02 The Picower Institute For Medical Research Compounds and methods of use to treat infectious diseases
WO1998037178A1 (en) 1997-02-24 1998-08-27 The Johns Hopkins University Immunomodulatory polypeptides derived from the invariant chain of mhc class ii
ATE302217T1 (de) 1997-05-02 2005-09-15 Us Gov Health & Human Serv Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
CA2205680A1 (en) 1997-05-16 1998-11-16 The University Of Western Ontario Clip immunomodulatory peptide
US6011005A (en) 1997-09-18 2000-01-04 The Picower Institute For Medical Research Prevention of pregnancy miscarriages
ES2198774T3 (es) 1997-11-05 2004-02-01 University Of Southern California Utilizacion de citoquinas y nitrogenos para inhibir respuestas inmunes patologicas.
RU2236251C2 (ru) 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
CA2389229A1 (en) 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity
US6268151B1 (en) 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
AU2001238677A1 (en) * 2000-02-28 2001-09-12 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
JP4202763B2 (ja) 2001-03-29 2008-12-24 サイトカイン・ファーマサイエンシズ・インコーポレーテッド マクロファージ遊走阻止因子レセプターとしてのｍｈｃクラスｉｉ不変鎖ポリペプチド使用のための方法及び組成物
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
US7205107B2 (en) 2001-12-21 2007-04-17 Cytokine Pharmasciences, Inc. Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease
US20050202010A1 (en) 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
CN105709237A (zh) 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
CN100457895C (zh) 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
PL3118223T3 (pl) * 2008-01-04 2021-04-06 Baxalta Incorporated Przeciwciała anty-mif do stosowania do leczenia chorób zapalnych
EP2079202A1 (en) * 2008-01-08 2009-07-15 NEC Corporation Method for optimizing the triggering of the transmission of buffer status reporting (BSR) information
IN2012DN05101A (cg-RX-API-DMAC10.html) 2010-01-19 2015-10-23 Immunomedics Inc
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker
EP2753937B1 (en) 2011-10-07 2018-01-17 Baxalta GmbH Characterization of cho-mif gene and protein, and use thereof

Similar Documents

Publication Publication Date Title
WO2013050453A4 (en) Oxmif as a diagnostic marker
Le Cann et al. Indoor environment and children's health: recent developments in chemical, biological, physical and social aspects
Kaur et al. Chemodosimeters: An approach for detection and estimation of biologically and medically relevant metal ions, anions and thiols
Lara et al. Applications of nanomaterials for immunosensing
Marjomäki et al. Site-specific targeting of enterovirus capsid by functionalized monodisperse gold nanoclusters
Nadar et al. Recent progress in nanostructured magnetic framework composites (MFCs): synthesis and applications
Yousef et al. (E)-N-(3-(1-(2-(4-(2, 2, 2-trifluoroacetamido) benzoyl) hydrazono) ethyl) phenyl) nicotinamide: a novel pyridine derivative for inhibiting vascular endothelial growth factor receptor-2: synthesis, computational, and anticancer studies
JP2015530971A5 (cg-RX-API-DMAC10.html)
JP2013500941A5 (cg-RX-API-DMAC10.html)
JP2006520781A5 (cg-RX-API-DMAC10.html)
JP2015535828A5 (cg-RX-API-DMAC10.html)
ME02837B (me) Monoklonsko protutijelo protiv psećeg interleukina-31
JP2014076062A5 (cg-RX-API-DMAC10.html)
JP2015529199A5 (cg-RX-API-DMAC10.html)
JP2016503295A5 (cg-RX-API-DMAC10.html)
JP2015529201A5 (cg-RX-API-DMAC10.html)
JP2016509585A5 (cg-RX-API-DMAC10.html)
Mori et al. Gut microbial signatures in sporadic and hereditary colorectal cancer
CN109844532A (zh) 分析生物数据的系统和方法
Rouah-Martin et al. Aptamer-based molecular recognition of lysergamine, metergoline and small ergot alkaloids
Perez Alamino et al. The great mimicker: IgG4-related disease
JP2012131808A5 (cg-RX-API-DMAC10.html)
Guk et al. Development of A4 antibody for detection of neuraminidase I223R/H275Y-associated antiviral multidrug-resistant influenza virus
Vassilakopoulos et al. Incorporating monoclonal antibodies into the first-line treatment of classical Hodgkin lymphoma
Earl et al. Somatic mutation profiling in the liquid biopsy and clinical analysis of hereditary and familial pancreatic cancer cases reveals KRAS negativity and a longer overall survival